April 7, 2025 04:08 PM EDT
Pharma
Marketing
Law

HHS says it may re­vis­it an­ti-obe­si­ty drug poli­cies af­ter drop­ping Biden-era pro­pos­al

Nicole DeFeudis

Editor

The gov­ern­ment said it “may con­sid­er fu­ture pol­i­cy op­tions” for an­ti-obe­si­ty med­ica­tions, af­ter de­clin­ing to fi­nal­ize a Biden-era pro­pos­al that would have ex­pand­ed cov­er­age to …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

New fund will pres­sure flail­ing biotechs, as in­vestor frus­tra­tion boils over

Ake­so shares new da­ta sug­gest­ing it can beat Keytru­da on sur­vival, wins Chi­na ap­proval

FDA chief Makary talks ex­pe­dit­ing drug ap­provals, RIFs and the abor­tion pill

Mer­ck KGaA clos­es in on Spring­Works deal at $3.5B price point

Ab­b­Vie com­mits $10B to ex­pand US foot­print with the threat of tar­iffs ahead

sponsored

AD­STI­LADRIN® (nad­o­fara­gene fi­rade­n­ovec-vncg) – A Grow­ing Body of Clin­i­cal Da­ta and Re­al-World Ev­i­dence

A service from the Financial Times